Nektar Presents 52-Week ResPEG Atopic Dermatitis Data, Eyes Q2 Phase 3 Launch
Nektar Therapeutics reported that its ResPEG candidate sustained clinical improvements through 52 weeks in moderate-to-severe atopic dermatitis patients with no new safety concerns. The company plans to initiate pivotal Phase 3 trials for its ophthalmology ResPEG program in the second quarter of 2026.
1. 52-Week Atopic Dermatitis Results
Nektar’s long-acting ResPEG therapy maintained robust disease control out to 52 weeks in patients with moderate-to-severe atopic dermatitis. Participants experienced durable reductions in skin lesions and itch severity with a consistent safety profile and no emerging adverse signals.
2. Ophthalmology Phase 3 Trial Plans
Following the positive dermatology data, Nektar is set to launch pivotal Phase 3 trials of ResPEG in an ophthalmic indication in Q2 2026. The study will evaluate both safety and efficacy endpoints in a larger patient cohort to support future regulatory filings.
3. Strategic Pipeline Implications
These milestones reinforce ResPEG’s potential as a multi-indication asset spanning dermatology and ophthalmology. Investors will watch for enrollment progress and late-2026 readouts that could pave the way for new market approvals.